As Magrolimab AML Studies Chug Along, The Question Becomes How To Combine It

Months after the US Food and Drug Administration lifted a hold on Gilead Sciences, Inc.’s CD47-targeting monoclonal antibody magrolimab, studies of the drug in acute myeloid leukemia (AML) have once again seen an enrollment resurgence. But even with potential approval a ways off, physicians are already thinking about how to combine it with other therapies, particularly in TP53-mutated AML patients, who have historically had worse outcomes.

The company presented data on 10 December at the American Society of Hematology annual meeting from a Phase I/II study of magrolimab combined with Bristol Myers Squibb Company’s hypomethylating...